contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


flerie-has-increased-its-holding-in-nanologica-whereby-an-obligation-to-make-a-mandatory-bid-arises

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Flerie

THIS PRESS RELEASE DOES NOT CONSTITUTE A PUBLIC TENDER OFFER OR OTHERWISE AN OFFER TO ACQUIRE SHARESFlerie AB:s wholly-owned subsidiary, Flerie Invest AB, Reg No. 556856-6615 (“Flerie”) has ...

<div class="mfn-preamble">THIS PRESS RELEASE DOES NOT CONSTITUTE A PUBLIC TENDER OFFER OR OTHERWISE AN OFFER TO ACQUIRE SHARES</div><div class="mfn-body">Flerie AB:s wholly-owned subsidiary, Flerie Invest AB, Reg No. 556856-6615 (“Flerie”) has today acquired 666,570 shares in Nanologica AB (publ), Reg. No. 556664-5023 (“Nanologica”). Flerie’s total holding in Nanologica following the acquisition amounts to 38,222,779 shares, comprising approximately 43.26 per cent of the total amount of shares and votes in the company.According to the Swedish Securities Council's statement AMN 2024:62, Flerie was granted an exemption from the obligation to make a mandatory bid that could arise as a result of Flerie (i) subscribing its share in the rights issue of units that Nanologica carried out in 2024, and (ii) utilised the warrants acquired through the rights issue for share subscription. According to the exception, an obligation to make a mandatory bid arises if Flerie subsequently acquires additional shares and thereby increases its voting rights in Nanologica.Through today's acquisition of additional shares in Nanologica, an obligation to make a mandatory bid arises. Flerie intends to revert with information regarding a possible public takeover bid regarding the remaining shares in Nanologica within four weeks.For further information, please contact:Cecilia Stureborg von Schéele, CFO of FlerieE-mail: ir@flerie.comThis information was submitted for publication on 25 April 2025 at 19.15 CEST.About FlerieFlerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit <a rel="noopener" href="http://www.flerie.com/">www.flerie.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/a3046c84-cd77-498b-aa12-891ec0680838/flerie-has-increased-its-holding-in-nanologica-whereby-an-obligation-to-make-a-mandatory-bid-arises.pdf" class="mfn-generated mfn-primary">Flerie has increased its holding in Nanologica, whereby an obligation to make a mandatory bid arises</a></div>

Flerie has increased its holding in Nanologica, whereby an obligation to make a mandatory bid arises